YCBD · cbdMD, Inc. · Executive Compensation
$0.48
-0.02 (-3.14%)
At close · Sep 9
Going-concern doubt
— flagged Aug 13, 2026
Substantial doubt about the company's ability to continue as a going concern.
“The Company’s ability to continue as a going concern is dependent upon its ability to improve profitability and cash flow and the ability to acquire additional funding. These and other factors raise substantial doubt about the Company’s ability to continue as a going concern within twelve months after the date that these financial statements are issued.”View the 10-Q filed Aug 13, 2026
Market Cap
$5.33M
Shares
11.21M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Ronan Kennedy | CEO and CFO | $275,000 |
| Bradley Whitford | Chief Accounting Officer | $181,375 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Ronan Kennedy | CEO and CFO | $275,000 |
| Bradley Whitford | Chief Accounting Officer | $191,435 |
| Kevin MacDermott | — | $109,615 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Ronan Kennedy | Interim CEO and CFO CFO and COO | $557,712 |
| Kevin MacDermott | President | $491,501 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| T. Ronan Kennedy | Chief Executive Officer and Chief Financial Officer | Appointed | 2025-11-28 |
Key facts
CIK
1644903
CUSIP
12482W408
13F (30d)
16 filings
16 filers
Visit website
Investor relations